

| | Pharmacokinetics | Use | Adverse effect | Contraindications |
|--|---|---|--|---|
| Dopamine Agonist Levodopa | -First –line treatment , combined with peripheral dopa decarboxylase inhibitor | All types of parkinsonism except those associated with antipsychotic drug therapy | -Peripheral side effects are anorexia, nausea, and vomiting (due to stimulation of the CTZ). Orthostatic hypotension ,Cardiac arrhythmias occur in some patients. -CNS adverse effects include vivid dreams, delusions, hallucinations, confusion and sleep disturbances. | -Psychotic patient. -Angle closure glaucoma. -active ulcer + melanoma |
| Dopamine Agonist Bromocriptine | -an ergot derivative, is an <u>agonist at the D2-receptors</u> - is absorbed to a variable extent from the GIT ; peak plasma levels are reached within 1–2 hours after an oral dose. - It is excreted in the bile and feces | - in conjunction with Levodopa to reduce the occurrence of side effects associated with long-term -for hyperprolactinemia | -Postural hypotension, nausea, somnolence -Dyskinesias. -Confusion, hallucinations, delusions, | -I psychotic illness . -myocardial infarction, -Active peptic ulceration. - peripheral vascular disease. |
| <u>Amantadine</u> | -originally introduced as an antiviral. -modestly effective in treating symptoms of parkinsonism. -Amantadine affects dopamine release and reuptake. -antagonist at muscarinic and NMDA receptors. | In early stages of parkinsonism as adjunct to levodopa therapy | -nausea, dizziness, insomnia, confusion, hallucinations, ankle edema, and livedo reticularis. -Amantadine and the anticholinergics may exert additive effects on mental functioning. | History of seizure and heartfailure |
| MAO inhibitor Selegiline | - an irreversible inhibitor of MAO-B, an important enzyme in the metabolism of dopamine. - Blockade of dopamine metabolism makes more dopamine available for stimulation of its receptors | -as monotherapy, may be effective in the newly diagnosed patient with parkinsonism - in conjunction with levodopa–carbidopa in later-stage parkinsonism to:- -reduce levodopa dosage requirements | -at higher doses Selegiline may inhibit MAO-A. -may cause insomnia when taken later during the day. -The adverse effects of levodopa may be increased by selegiline. -Selegiline should not be coadministered with TCA, meperidine or SSRIs. (may cause hyperpyrexia, agitation, delirium, coma). | |
| <u>Anticholinergic Drugs</u> Benztropine, Trihexyphenidyl | - The efficacy of anticholinergic drugs in parkinsonism is due to their ability to block muscarinic receptors in the striatum | used during the early stages of the disease or as an adjunct to levodopa therapy. | -cycloplegia, dry mouth, urinary retention, and constipation. -Confusion, delirium, and hallucinations may occur at higher doses. -Trihexyphenidyl may cause withdrawal symptoms in patients receiving large doses. | |